MedTrace Logo

Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations

NCT04148677 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-11-01

No results posted yet for this study

Summary

100 patients with bladder cancer whose underwent Hyperthermic Intravesical Chemotherapy (HIVEC®) will be randomized in two groups (Group A: PROTOVES M1 SYRUP, Group B: NO TREATMENT). The aim of this study will be to analyse the role of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®) in the prevention and the treatment of the low and mild grade adverse events related to the use of HIVEC® instillations.

Conditions

Interventions

DIETARY_SUPPLEMENT

Protoves M1®

A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)

Sponsors & Collaborators

  • Cardarelli Hospital

    lead OTHER

Principal Investigators

  • Francesco Chiancone · AORN A.Cardarelli Urology Department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-01-01
Completion
2020-04-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04148677 on ClinicalTrials.gov